AlphAIAlphAI — Financial news for AI agents
quiverquant.com$MRNA

MODERNA ($MRNA) Releases Q3 2026 Earnings

Moderna (MRNA) reported Q3 2026 earnings of $0.38 per share, exceeding estimates by $1.66. Revenue was $1.31 billion, surpassing expectations by $410.25 million. Insiders sold shares, while hedge funds had mixed activity. Analysts' price targets range from $38 to $77.

Original reporting
quiverquant.com
Published Nov 6, 2026, 12:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 12:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
MODERNA ($MRNA) Releases Q3 2026 Earnings — source image
Source · quiverquant.com
Decision brief

The 30-second read

$MRNABullishHigh
01

Why it matters

The surprise earnings could trigger short‑term buying, especially in after‑hours trading, while longer‑term valuation will depend on pipeline progress.

02

Market read

First‑report earnings beat for a large‑cap biotech, high relevance for short‑term traders.

03

What to watch

Potential concerns about future pipeline milestones and regulatory risks are not reflected in the earnings beat.

Relevance 8/10Novelty 8/10Timing: after‑hours Friday release

Background

Moderna (MRNA) released its Q3 2026 earnings, showing EPS of $0.38 versus a -$1.28 consensus and revenue of $1.313 B versus $902.8 M consensus.

Company-level read

Ticker impact

$MRNABullishHigh confidence
Context

Moderna reported Q3 2026 earnings beating EPS and revenue estimates, providing fresh material for traders.

Expected impact

likely upward as the market prices in the earnings surprise

Evidence & confidence

The beat on both EPS and revenue is a material, first‑report event for a large‑cap biotech, prompting short‑term buying interest.

Market effects

Sector

Biotech sector may see broader rally on positive earnings momentum.

Regional

U.S. markets likely to open higher on biotech optimism.

Global

Moderna's results could influence global vaccine and mRNA technology sentiment.

Counterpoint

What could challenge this read

Some investors may view the beat as already priced in, expecting a pull‑back.

Key entities

  • Executive
    Stephen Hoge

    President, sold 318,952 shares in the past six months.

  • Executive
    Stephan Bancel

    CEO, sold 499,246 shares in the past six months.

Read at source← All news

StoryModerna posts Q3 profit, beats revenue estimates and lifts 2026 growth outlook

Also covered by

5 outlets

Related articles

$MRNAHighAI 9/10

MRNA Q3 Earnings Beat on COVID Sales, Raises '26 Outlook, Stock Rises

Moderna (MRNA) reported Q3 2026 EPS of $0.38, beating estimates by $1.48. Revenue rose 29.2% YoY to $1.31B, driven by international COVID-19 vaccine sales. The company raised its 2026 sales outlook to 15-25% growth and reduced R&D spending plans. Shares rose in pre-market trading. Key products include mFlusiva and mCoflu vaccines, with mixed pipeline results.

zacks.com
$MRNAMedAI 8/10

WHO adds two more Ebola vaccines to clinical trial

WHO adds two Ebola vaccines, ChAdOx1 and mRNA-1469, to clinical trial in DRC. Developed by Oxford/Serum Institute and Moderna, they target the Bundibugyo virus. WHO's advisory group recommended further evaluation. Trial led by Institut National de Recherche Biomédicale and others. Current outbreak has caused over 4,600 cases and 2,100 deaths.

finance.yahoo.com
$MRNAMedAI 8/10

Moderna enjoys stable vaccine sales thanks to global COVID uptake

Moderna reported a 29% revenue increase to $1.3 billion for the quarter, driven by global COVID-19 vaccine sales. CFO Jamey Mock attributed growth to higher uptake of mNEXSPIKE and Spikevax. U.S. revenue is declining, but global expansion is leading sales. Moderna raised annual revenue expectations to 15-25%. Analysts noted strong vaccine sales and potential market share gains in the EU post-Pfizer's contract expiration.

biospace.com
$MRNAHighAI 8/10

What Moderna (MRNA) Said on Its Q3 Earnings Call

Moderna reported a 27% drop in R&D expenses to $583M in Q3, while SG&A expenses rose 5% to $282M. The company reduced its full-year R&D and capital expenditure estimates. Cash and investments increased to $8B. Moderna expects year-end cash of $8.1B-$8.3B. It announced progress in melanoma, renal cell carcinoma, and pancreatic cancer studies, and received FDA approval for its flu vaccine mFLUSIVA. The norovirus vaccine candidate did not meet interim success criteria.

finance.yahoo.com